ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
Harnessing the metastatic potential of human osteosarcoma cells by natural coumarin galbanic acid.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Coumarins in musculoskeletal health: a systematic review.Frontiers in nutrition · 2026Pooled it
- Natural Coumarins Galbanic Acid and Auraptene Improved the Efficacy of Alkeran on Human Osteosarcoma Cells by Targeting ABC Transporters.Chemistry & biodiversity · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma (OS), the most common primary malignant bone tumor in children and adolescents, presents a significant challenge due to its high propensity for metastasis. This reality underscores the urgent need for innovative therapies targeting metastatic progression to improve patient outcomes. The present study aimed to investigate the potential of galbanic acid (GBA), a natural sesquiterpene coumarin, on the metastasis of OS cells for the first time. Utilizing bioinformatics tools, shared therapeutic targets between GBA and OS were identified, with key hub genes prioritized through network analysis. Molecular docking and dynamics simulations were performed to assess the binding affinity and stability of GBA with MMP-2, MMP-9, ADAM17, and ADAMTS5. For experimental validation, GBA was isolated from Ferula szowitsiana via thin-layer chromatography, and its effects on MG-63 cells were evaluated through a series of assays: alamarBlue assay and flow cytometry for viability and apoptosis, scratch assay for migration, transwell assay for invasive potential, fibronectin adhesion assay for cell-matrix interaction, and gelatin zymography for MMP activity. Computational analyses revealed MMPs and ADAMs as common targets of GBA and OS. Molecular docking and dynamics simulations indicated strong and stable interactions between GBA with MMP-2, MMP-9, ADAM17, and ADAMTS5. Experimental studies revealed that treatment with 100 μM GBA did not induce significant toxicity in MG-63 cells. However, GBA significantly (p < 0.01) altered cell migration, invasion, and adhesion, which was associated with a marked reduction in the enzymatic activity of MMP-2 and MMP-9. This research highlights the therapeutic potential of GBA in mitigating the metastatic properties of OS cells, suggesting a promising avenue for future treatment strategies.
Indexed as
Identifiers
40192795What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.